Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Shivlal Pandey"'
Autor:
Shaji Kumar, Arleigh McCurdy, Suzanne R. Hayman, John A. Lust, Shivlal Pandey, S V Rajkumar, Francis K. Buadi, Martha Q. Lacy, Morie A. Gertz, Stephen J. Russell, Angela Dispenzieri, Steven R. Zeldenrust, Robert A. Kyle, David Dingli, Prashant Kapoor, Nelson Leung
Publikováno v:
Leukemia
Therapy for multiple myeloma (MM) has markedly changed in the past decade with the introduction of new drugs, but it is not clear whether the improvements have been sustained. We studied 1038 patients diagnosed between 2001 and 2010, grouping patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9ba21edd6adda2e58752506465469b4
https://doi.org/10.1038/leu.2013.313
https://doi.org/10.1038/leu.2013.313
Publikováno v:
Echocardiography. 29:502-504
Live/real time three-dimensional transthoracic echocardiography (3DTTE) provides an incremental value in the delineation of various cardiac pathologies. In this study, two-dimensional transthoracic echocardiography (2DTTE) of a 56-year-old patient sh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d929c453278d4026e5f495e8d1b5b2cc
https://doi.org/10.1111/j.1540-8175.2011.01673.x
https://doi.org/10.1111/j.1540-8175.2011.01673.x
Autor:
Shaji Kumar, Shivlal Pandey, Francis K. Buadi, Angela Dispenzieri, Morie A. Gertz, David Dingli, Prashant Kapoor, Manish J. Gandhi, Muhammad A. Mir, William J. Hogan, Martha Q. Lacy, Suzanne R. Hayman
Publikováno v:
Clinical lymphoma, myelomaleukemia. 15(6)
Background Allogeneic transplant in myeloma remains controversial. Patients and Methods We performed a retrospective review of 76 patients in the Mayo Clinic database from 1993 to 2013 who underwent allogeneic hematopoietic stem cell transplant (HSCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84614a39830080dca07c3a2bac6a52d5
https://pubmed.ncbi.nlm.nih.gov/25958193
https://pubmed.ncbi.nlm.nih.gov/25958193
Autor:
Shivlal, Pandey, Robert A, Kyle
Publikováno v:
Oncology (Williston Park, N.Y.). 27(8)
Immunoglobulin D multiple myeloma (IgD MM) accounts for almost 2% of all myeloma cases. It is associated with an increased frequency of undetectable or small monoclonal (M)-protein levels on electrophoresis; osteolytic lesions; extramedullary involve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b2cd05561af684422464e89f76525563
https://pubmed.ncbi.nlm.nih.gov/24133831
https://pubmed.ncbi.nlm.nih.gov/24133831
Publikováno v:
Echocardiography (Mount Kisco, N.Y.). 29(4)
Live/real time three-dimensional transthoracic echocardiography (3DTTE) provides an incremental value in the delineation of various cardiac pathologies. In this study, two-dimensional transthoracic echocardiography (2DTTE) of a 56-year-old patient sh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5aceb95141e58c8d07017d48e9c4045f
https://pubmed.ncbi.nlm.nih.gov/22404456
https://pubmed.ncbi.nlm.nih.gov/22404456
Autor:
Arleigh McCurdy, Shaji Kumar, Stephen J. Russell, Martha Q. Lacy, Robert A. Kyle, David Dingli, Shivlal Pandey, Angela Dispenzieri, Vincent Rajkumar, Morie A. Gertz, Utkarsh Painuly, Prashant Kapoor, Francis K. Buadi, John A. Lust, Suzanne R. Hayman
Publikováno v:
Blood. 122:2136-2136
Background Multiple myeloma (MM) is uncommon in patients below 40 years of age. Between 1960 and 1992 when stem cell transplantation (SCT) was rarely performed and novel agents were unavailable, overall survival (OS) was reported to be 54 months in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef8746f894fef21c0fd8244df6debcc2
https://doi.org/10.1182/blood.v122.21.2136.2136
https://doi.org/10.1182/blood.v122.21.2136.2136
Autor:
Shivlal Pandey, S. Vincent Rajkumar, Prashant Kapoor, Rhett P Ketterling, Martha Q Lacy, Morie A Gertz, Francis Buadi, David Dingli, Suzanne R Hayman, Angela Dispenzieri, Shaji K Kumar
Publikováno v:
Blood. 122:3210-3210
Background Multiple myeloma (MM) is a heterogeneous disease with variable responses to different therapeutic regimens and wide spectrum of survival. Much of the heterogeneity in the outcomes appear to be related to the underlying primary genetic abno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::600c5d9f76a9194116ed657b571c0ba2
https://doi.org/10.1182/blood.v122.21.3210.3210
https://doi.org/10.1182/blood.v122.21.3210.3210
Autor:
Shivlal Pandey, Morie A. Gertz, Angela Dispenzieri, Stephen J. Russell, Steven R. Zeldenrust, Shaji Kumar, John A. Lust, Prashant Kapoor, Martha Q. Lacy, Robert A. Kyle, Arleigh McCurdy, S. Vincent Rajkumar, Francis K. Buadi, Suzanne R. Hayman, David Dingli
Publikováno v:
Journal of Clinical Oncology. 31:8541-8541
8541 Background: Achievement of a complete response (CR) to treatment is an important predictor of outcome for patients (pts) with myeloma (MM). The goal of the current study was to assess whether the treatment that resulted in CR has any impact on t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c721dd0f53b7f6fc606e6c2d52099d3
https://doi.org/10.1200/jco.2013.31.15_suppl.8541
https://doi.org/10.1200/jco.2013.31.15_suppl.8541